NEWS FROM THE STANDARD |
 |
Bristol-Myers to Buy DuPont Drug Unit for $7.8 Billion
Jun 07 2001 05:22 PM PDT
PROFILE |
 |
Dieters can control their midsections with Knoll's Meridia, a drug touted as supplementing, not replacing, lifestyle changes for the obese. Founded in 1886 and now a subsidiary of Abbott Laboratories (which bought the company from Germany's chemicals giant BASF), Knoll develops and makes drugs to treat pain, heart disease, cancer, autoimmune and nervous system dysfunctions, and other diseases and disorders. Its products include thyroid replacement hormone SYNTHROID, painkiller Vicoprofen, and Isoptin for heart disease. Knoll expands its product portfolio by forming strategic partnerships and marketing collaborations.
COMPETITION |
 |
GlaxoSmithKline plc (GSK)
Johnson & Johnson (JNJ)
Merck & Co., Inc. (MRK)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1998 Sales (mil.): 690.90
1-Yr. Sales Growth: 5.1%
Employees: 3,205
Revenue per employee: $215,569.42
KEY PEOPLE |
 |
Dieter Wagner
CEO
CONTACT INFO |
 |
Knollstrasse 50
67061 Ludwigshafen 67008, Germany
Phone: 49-621-589-0
Fax: 49-621-589-1562
Online: Web Site
|